The Chosun Ilbo on MSN
Kolon TissueGene's TG-C fails US phase 3 trial
C’ (formerly Invossa) failed to demonstrate therapeutic efficacy in its first U.S. Phase 3 clinical trial. Jeon Seng-ho, ...
ACTiVION-II, the first of two US Phase 3 clinical trials, did not meet co-primary endpoints of VAS pain score and WOMAC® total score at Month 12Results from ACTiVION-I, the second Phase 3 trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results